After Bloomberg said that Dentsply Sirona is exploring a possible sale of its Wellspect urology catheter business with a $1B price tag suggested, Piper Sandler analyst Jason Bednar pointed out that Bloomberg did have a similar report in 2017, but added that "this time could be different, though" and said "this report could have legs to it." The firm sees the merits of management’s desire to strategically focus exclusively on the dental market and thinks potential proceeds from Wellspect could be deployed to "other shareholder friendly areas." Piper has a Neutral rating and $29 price target on Dentsply Sirona shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on XRAY:
- Dentsply Sirona weighing possible carve-out of Wellspect, Bloomberg says
- Dentsply Sirona upgraded to Market Perform from Underperform at William Blair
- Piper keeps Neutral on Dentsply Sirona, says Q4 results ‘mildly encouraging’
- Dentsply Sirona to Present at J.P. Morgan Healthcare Conference, Provides Update on Anticipated Full Year 2022 Results
- Dentsply Sirona sees 2022 adjusted EPS $1.90-$2.00, consensus $1.96